Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.
Current Value
$28.801 Year Return
Current Value
$28.801 Year Return
Market Cap
$808.57M
P/E Ratio
144.42
1Y Stock Return
48.97%
1Y Revenue Growth
62.43%
Dividend Yield
0.00%
Price to Book
1.8
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CYCN | 0.02% | $4.77M | -16.19% | 0.00% |
QNRX | -0.03% | $3.20M | -85.07% | 0.00% |
PG | -0.07% | $402.15B | +14.14% | 2.33% |
NTZ | -0.10% | $47.64M | -30.94% | 0.00% |
CAH | -0.17% | $28.64B | +12.14% | 1.70% |
POAI | 0.19% | $4.29M | -78.60% | 0.00% |
WLKP | -0.24% | $796.39M | +4.00% | 8.34% |
VIRT | 0.29% | $3.17B | +110.38% | 2.60% |
ARC | 0.32% | $146.66M | +18.95% | 5.90% |
MAGN | -0.42% | $638.97M | -3.42% | 0.00% |
DUOL | 0.48% | $14.17B | +49.85% | 0.00% |
GIS | 0.51% | $34.85B | -2.91% | 3.78% |
WRAP | 0.53% | $62.86M | -49.45% | 0.00% |
QXO | -0.69% | $6.51B | -35.95% | 0.00% |
GAN | 0.69% | $83.39M | +21.19% | 0.00% |
RNR | 0.70% | $13.74B | +23.09% | 0.58% |
QTTB | 0.71% | $354.34M | +188.64% | 0.00% |
CLW | 0.78% | $413.53M | -30.06% | 0.00% |
ACRS | 0.79% | $327.87M | +415.67% | 0.00% |
HUM | -0.82% | $33.45B | -45.22% | 1.25% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
HRL | -19.74% | $16.30B | -8.38% | 3.81% |
VERX | -16.15% | $7.99B | +89.70% | 0.00% |
KODK | -15.66% | $422.90M | +41.40% | 0.00% |
APRE | -13.97% | $16.41M | -19.47% | 0.00% |
HLN | -12.74% | $42.91B | +13.94% | 1.67% |
PULM | -12.42% | $19.83M | +202.98% | 0.00% |
PSTG | -11.93% | $16.35B | +36.41% | 0.00% |
TPST | -11.03% | $37.75M | -77.59% | 0.00% |
KR | -10.86% | $42.03B | +35.08% | 2.11% |
COR | -10.43% | $47.48B | +21.20% | 0.86% |
MCK | -9.83% | $78.15B | +35.51% | 0.42% |
OXBR | -9.32% | $19.05M | +178.18% | 0.00% |
SYPR | -7.70% | $32.23M | -26.32% | 0.00% |
HUSA | -7.34% | $16.69M | -11.56% | 0.00% |
OKTA | -7.28% | $12.66B | +4.91% | 0.00% |
STVN | -6.95% | $4.95B | -32.48% | 0.32% |
STRA | -6.77% | $2.33B | +6.80% | 2.53% |
MSDL | -6.74% | $1.83B | +0.66% | 7.26% |
NOC | -6.55% | $71.54B | +4.23% | 1.60% |
VSTA | -6.46% | $204.94M | -39.33% | 0.00% |
Yahoo
FRIENDSWOOD, Texas, November 20, 2024--Castle's executive management will present a company overview at the Piper Sandler 36th Annual Healthcare Conference on Dec. 4, 2024, at 10:50 am ET
Yahoo
The CHMP's opinion is based on late-stage data, which show that treatment with AZN's Tagrisso extends progression-free survival by more than three years in certain NSCLC patients.
Yahoo
FRIENDSWOOD, Texas, November 19, 2024--Castle has been named a Houston Top Workplace by the Houston Chronicle for the 4th straight year and has earned 3 national Culture Excellence awards
Yahoo
The CHMP's opinion is based on late-stage study data, which show that treatment with JNJ's combo drug reduces the risk of disease progression or death by 30% in certain NSCLC patients.
Yahoo
Avidity Biosciences expands its pipeline to include two new drugs targeting rare genetic cardiomyopathies.
Yahoo
RGEN reports better-than-expected third-quarter results. While management lowers its guidance for 2024 total sales, it raises the same for EPS.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
DAVA | 47.67% | $1.16B | -59.28% | 0.00% |
FA | 47.51% | $3.04B | +17.64% | 0.00% |
TRS | 46.01% | $1.06B | +9.03% | 0.61% |
FLGT | 39.89% | $519.98M | -37.82% | 0.00% |
INN | 39.47% | $661.35M | -1.61% | 4.92% |
MQ | 38.64% | $1.96B | -36.48% | 0.00% |
SDGR | 38.45% | $1.38B | -35.46% | 0.00% |
NVCR | 38.33% | $1.78B | +34.75% | 0.00% |
DMRC | 37.27% | $694.39M | -2.06% | 0.00% |
XMTR | 37.03% | $1.48B | +50.13% | 0.00% |
GH | 36.65% | $3.79B | +33.86% | 0.00% |
PLRX | 36.63% | $778.32M | -9.55% | 0.00% |
RCKY | 36.46% | $155.86M | -17.74% | 2.95% |
ONL | 36.46% | $218.76M | -20.85% | 10.31% |
AMPH | 35.75% | $2.10B | -23.00% | 0.00% |
JAZZ | 35.71% | $7.06B | -1.23% | 0.00% |
CNOB | 35.47% | $1.03B | +41.32% | 2.65% |
ORC | 35.19% | $615.55M | +6.95% | 18.46% |
BRKL | 35.19% | $1.08B | +30.28% | 4.48% |
RXST | 35.04% | $1.82B | +62.89% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
DBMF | -0.61% | $1.02B | 0.85% |
COMT | 0.72% | $829.06M | 0.48% |
GSG | 0.79% | $914.42M | 0.75% |
DBE | -0.81% | $50.13M | 0.77% |
DBA | -0.86% | $755.88M | 0.93% |
KCCA | -0.97% | $220.51M | 0.87% |
CCOR | -0.97% | $109.04M | 1.18% |
ULST | -1.12% | $535.47M | 0.2% |
BSCO | -1.20% | $2.35B | 0.1% |
JBBB | 1.42% | $1.26B | 0.49% |
HDRO | 1.44% | $164.26M | 0.3% |
DBO | -1.50% | $217.57M | 0.77% |
TBIL | -1.56% | $4.38B | 0.15% |
USCI | 1.70% | $185.47M | 1.07% |
DBC | 1.74% | $1.39B | 0.87% |
FTGC | 1.98% | $2.17B | 1.02% |
PDBC | 1.98% | $4.40B | 0.59% |
XBIL | -2.04% | $637.70M | 0.15% |
CLOI | 2.10% | $715.40M | 0.4% |
FTSM | -2.26% | $6.08B | 0.45% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -30.36% | $388.04M | 1.43% |
VIXY | -25.11% | $195.31M | 0.85% |
TAIL | -19.02% | $67.98M | 0.59% |
TPMN | -14.47% | $40.60M | 0.65% |
USDU | -14.05% | $201.97M | 0.5% |
UUP | -13.98% | $309.25M | 0.77% |
CORN | -10.82% | $61.12M | 0.2% |
XHLF | -10.33% | $874.27M | 0.03% |
WEAT | -9.74% | $120.27M | 0.28% |
CTA | -8.01% | $350.27M | 0.78% |
SGOV | -7.90% | $27.53B | 0.09% |
FMF | -7.15% | $244.61M | 0.95% |
SOYB | -6.69% | $27.32M | 0.22% |
KMLM | -6.61% | $353.87M | 0.9% |
EQLS | -6.38% | $76.08M | 1% |
MINT | -3.93% | $11.62B | 0.35% |
SHYD | -3.40% | $311.50M | 0.35% |
BILZ | -3.32% | $563.02M | 0.14% |
HIGH | -3.15% | $302.78M | 0.51% |
SHV | -2.98% | $18.13B | 0.15% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XHE | 46.61% | $213.41M | 0.35% |
GNOM | 46.17% | $70.59M | 0.5% |
FXD | 45.44% | $1.54B | 0.61% |
ARKG | 45.35% | $1.13B | 0.75% |
EDOC | 45.26% | $40.86M | 0.68% |
IVOO | 44.68% | $2.38B | 0.1% |
PTH | 43.24% | $143.31M | 0.6% |
ISCG | 43.23% | $640.00M | 0.06% |
SFYX | 42.87% | $105.21M | 0.06% |
EZM | 42.82% | $823.84M | 0.38% |
VTWO | 42.80% | $12.38B | 0.1% |
XBI | 42.79% | $6.58B | 0.35% |
PBE | 42.70% | $258.53M | 0.58% |
ESML | 42.69% | $1.90B | 0.17% |
IWM | 42.51% | $75.73B | 0.19% |
NUSC | 42.50% | $1.27B | 0.31% |
IWO | 42.13% | $12.56B | 0.24% |
DES | 42.13% | $2.13B | 0.38% |
SMMD | 42.06% | $1.24B | 0.15% |
VXF | 41.93% | $21.54B | 0.06% |